Galantamine (Galanthamine)

A benzazepine derived from norbelladine. It is found in GALANTHUS and other AMARYLLIDACEAE. It is a cholinesterase inhibitor that has been used to reverse the muscular effects of GALLAMINE TRIETHIODIDE and TUBOCURARINE and has been studied as a treatment for ALZHEIMER DISEASE and other central nervous system disorders.

Also Known As:

Networked: 686 relevant articles (87 outcomes, 184 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Bastida, Jaume: 10 articles (01/2015 - 10/2002)
2.	Albuquerque, Edson X: 10 articles (12/2011 - 05/2002)
3.	López, Manuela G: 9 articles (09/2013 - 01/2004)
4.	Pereira, Edna F R: 9 articles (12/2011 - 05/2002)
5.	Bullock, Roger: 9 articles (01/2009 - 04/2002)
6.	Maelicke, Alfred: 8 articles (01/2015 - 05/2002)
7.	Viladomat, Francesc: 8 articles (09/2013 - 10/2002)
8.	García, Antonio G: 8 articles (09/2010 - 01/2004)
9.	Codina, Carles: 7 articles (08/2012 - 10/2002)
10.	Rockwood, Kenneth: 7 articles (12/2011 - 01/2003)

Related Diseases

1.	Alzheimer Disease (Alzheimer's Disease) 01/01/2012 - "Alzheimer's Disease Assessment Scale - cognitive subscale (ADAS-cog/11) scores improved significantly from baseline in both treatment arms, with a significant difference in favor of galantamine on the "language" functional area (P = 0.035). " 04/11/2006 - "Clinicians, but not patients and caregivers, observed a significantly greater improvement in goal attainment among patients with mild to moderate Alzheimer's disease who were taking galantamine than among those who were taking placebo." 01/01/2001 - "The alkaloid (-)-galanthamine is known to produce significant improvement of cognitive performances in patients with the Alzheimer's disease. " 12/09/2000 - "At six months, patients who received galantamine had a significantly better outcome on the 11 item cognitive subscale of the Alzheimer's disease assessment scale than patients in the placebo group (mean treatment effect 2.9 points for lower dose and 3.1 for higher dose, intention to treat analysis, P<0.001 for both doses). " 07/01/2012 - "This may make galantamine an attractive option for patients starting treatment for Alzheimer's disease (AD), but also for those who have not benefited from their current therapy. "
2.	Dementia (Dementias) 11/15/2002 - "For example, behavioral symptoms, which can be more severe in VaD than in AD and are important determinants of the impact of dementia, may be especially benefited by galantamine. " 01/01/2006 - "The results of the study revealed high efficacy of reminyl in the treatment of patients with mild and moderate dementia and good tolerability of the medication." 11/15/2002 - "Significant cognitive improvements over 6 months, long-term maintenance of cognition for at least 12 months, and global benefits, as well as efficacy in both behavioral and functional symptoms, indicate efficacy with galantamine that is so far unsurpassed by any other drug treatment for dementia. " 12/01/2001 - "Being approved for the treatment of mild-to-moderately severe AD in both the US and in Europe, with trials of its efficacy in other dementia types already yielding positive results, galantamine ranks as a first-line therapy for dementia." 05/01/2013 - "Several studies have evaluated the efficacy of galantamine in dementia, it is not clear whether it has an effect on platelet function. "
3.	Vascular Dementia (Subcortical Arteriosclerotic Encephalopathy) 07/31/2007 - "Galantamine was effective for improving cognition, including executive function, in patients with vascular dementia, with good safety and tolerability. " 01/01/2013 - "Significantly higher numbers of patients dropped out, (102/396 galantamine, 33/196 placebo odds ratio (OR)1.71, 95% CL 1.11 to 2.65, P = 0.02) and withdrew due to an adverse event from the group treated with galantamine compared with the placebo group (79/396 galantamine, 16/196 placebo, OR 2.80, 95% CI 1.59 to 4.95, P =0.0004).Data were also included from a second larger trial (GAL-INT-26) involving 788 patients with vascular dementia diagnosed using standard criteria. " 07/31/2007 - "Galantamine treatment of vascular dementia: a randomized trial." 01/01/2003 - "Patients with probable vascular dementia treated with galantamine for 6 or 12 months showed significant improvements in ADAS-cog/11 scores versus baseline, which were maintained at the end of the 12-month study. " 01/01/2002 - "Galantamine has been shown to delay the onset of BPSD in mild to moderate AD patients in one placebo-controlled study, and improve BPSD in a similar study of patients with cerebrovascular disease or probable vascular dementia. "
4.	Bipolar Disorder (Mania) 04/01/2006 - "To determine if galantamine is effective in the treatment of chronic cognitive impairment in bipolar disorder. " 06/01/2009 - "The purpose of this study was to determine whether galantamine augmentation improved cognition in patients with euthymic bipolar disorder. " 01/01/2009 - "Nineteen subjects with bipolar disorder in remission, who reported subjective cognitive deficits, were treated with open-label galantamine-ER 8-24 mg/day for 4 months. " 01/01/2009 - "Galantamine-ER for cognitive dysfunction in bipolar disorder and correlation with hippocampal neuronal viability: a proof-of-concept study." 06/01/2009 - "Galantamine may thus have specific benefits for episodic memory, but not processing speed, in patients with cognitive impairment as part of bipolar disorder."
5.	Neurobehavioral Manifestations 06/01/2008 - "This double-blind, randomized, placebo-controlled pilot study was designed to assess the safety and efficacy of galantamine augmentation of antidepressant treatment for depressive and cognitive symptoms in older adults with major depression. " 01/01/2007 - "Clinical studies suggest that adjunct galantamine may improve negative and cognitive symptoms in schizophrenia. " 04/01/2005 - "This review was conducted in order to determine the efficacy of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease, and also to determine whether galantamine was a superior pharmacological intervention. " 10/01/2005 - "Adjuvant galantamine to risperidone improves negative and cognitive symptoms in a patient presenting with schizophrenialike psychosis after traumatic brain injury." 04/01/2005 - "A comparison of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease: a meta-analysis."

Related Drugs and Biologics

1.	donepezil (Aricept)
2.	rivastigmine (Exelon)
3.	Cholinesterase Inhibitors (Anticholinesterases)
4.	Memantine (Namenda)
5.	Acetylcholinesterase
6.	Cholinesterases (Cholinesterase)
7.	Galantamine (Galanthamine)
8.	Tacrine (Cognex)
9.	Nicotinic Receptors (Nicotinic Acetylcholine Receptor)
10.	Ginkgo biloba extract 761 (Rokan)

Related Therapies and Procedures

1.	Activities of Daily Living (ADL)
2.	Aftercare (After-Treatment)
3.	Drug Therapy (Chemotherapy)
4.	Home Nursing (Nursing, Home)
5.	Transdermal Patch